Feel free to ask any questions, leave your comments, wishes and suggestions regarding the Google Translation at our Telegram Chat.
Like this video
Share this ICO with friends and colleagues
Team Xeophin (PreICO)
Developing a suite of Class Leading Immunotherapeutics
Xeophin has devised a funding pathway to develop the XeRA-1 Therapeutic for Rheumatoid Arthritis, however this offering represents much more than stake in a promising pharmaceutical. Xeophins’ unique approach to Biotech funding can change the paradigm of how medicine is financed. Xeophin is tokenizing 50% of the future royalties generated by XeRA-1, allowing its’ token holders to fund, and benefit from its’ success.
Our mission is to take our core technologies and drive them through our six step process. The outcome being a transaction-ready and IP protected technology portfolio, tokenized. From then on, Xeophin will undertake commercialization activities to achieve a significant royalty deal, delivering value to our XeRA-1 Token holders.
Being backed by a physical asset, the XeRA-1 Arthritis Therapeutic, the XERA1 token can increase in value as milestones are hit on the road to commercialization. Once live, token holders will yield cash royalty payments, commensurate to XeRA-1s’ earnings.